A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 27 Dec 2017 Planned number of patients changed from 20 to 39.
- 10 Nov 2017 Results presened in an IRX Therapeutics Media Release.
- 10 Nov 2017 According to an IRX Therapeutics media release, preliminary results be presented on Saturday, November 11 at the Society for Immunotherapy of Cancers (SITC) 31st Annual Meeting.